Beckers Henny J M

XENGel Stent compared to PRESERFLO™ MicroShunt implantation for primary open-angle glaucoma: two-year results.

Xen Gel Stent and PreserFlo MicroShunt implantations achieved comparable results in POAG eyes in terms of IOP-lowering and surgical success, with a similar high safety profile.

Safety and Effectiveness of the PRESERFLO® MicroShunt in Primary Open-Angle Glaucoma: Results from a 2-Year Multicenter Study.

In this study, mean IOP and glaucoma medication reductions were significant and sustained over 2 years postsurgery. No long-term, sight-threatening AEs were reported. Further studies may confirm potential risk/benefits of higher MMC concentration.

Micropulse Trans-scleral Cyclophotocoagulation in Patients With Glaucoma: 1- and 2-Year Treatment Outcomes.

Micropulse TSCPC is a safe and effective treatment for lowering both IOP and the number of IOP-lowering medications.

Outcomes of severe uveitic glaucoma treated with Baerveldt implant: can blindness be prevented?

The BGI is an effective and safe treatment for patients with refractive secondary glaucoma due to uveitis.

Small RNA Sequencing of Aqueous Humor and Plasma in Patients With Primary Open-Angle Glaucoma.

Small RNA sequencing identified seven differentially expressed miRNAs in AH of POAG patients. The differentially expressed miRNAs may be useful as POAG biomarkers or could become targets for new therapeutic strategies.

Early Phacoemulsification After Acute Angle Closure in Patients With Coexisting Cataract.

Early phacoemulsification with intraocular lens implantation results in a reduced intraocular pressure and number of glaucoma medications after an acute angle closure glaucoma crisis in patients with coexisting cataract.

Comprehensive bioinformatics analysis of trabecular meshwork gene expression data to unravel the molecular pathogenesis of primary open-angle glaucoma.

This study provides an overview of the processes involved in the molecular pathogenesis of POAG in the TM.

Risk Factors for the Development of Ocular Hypertension After Keratoplasty: A Systematic Review.

Risk factors with a definite association can help clinicians select patients at risk and adjust their follow-up and treatment. The other factors need further investigation.

Wound Healing Response After Bleb-Forming Glaucoma Surgery With a SIBS Microshunt in Rabbits.

Implantation of a poly(styrene-b-isobutylene-b-styrene) microshunt in rabbits resulted in the occurrence of a wide variety of cells during the wound-healing response.

Intraocular Pressure Fluctuations and 24-Hour Continuous Monitoring for Glaucoma Risk in Wind Instrument Players.

IOP often rises after playing wind instruments, but similar or even higher IOP levels seem to occur during common other daily activities or at night.

Five-year follow-up with the PreserFlo MicroShunt for open-angle glaucoma.

After five years, the MicroShunt was found to be a safe procedure, leading to a sustained reduction in mean IOP and number of IOP-lowering medications.

Ab-Externo MicroShunt vs. Trabeculectomy in Primary Open-Angle Glaucoma: 5-Year Safety Results from a Randomized, Multicenter Study.

Both filtering procedures demonstrated favorable safety profiles over 5 years.

Corneal endothelial cell loss after Baerveldt glaucoma drainage device implantation in the anterior chamber.

The TC distance is of significant influence on corneal ECD, a shorter TC distance causing more severe EC loss, especially in the PQC.

A Systematic Review of End-of-Life Visual Impairment in Open-Angle Glaucoma: An Epidemiological Autopsy.

CONCLUSIONS: Further prevention of blindness in glaucoma patients is needed.

Prediction of Glaucomatous Visual Field Progression Using Baseline Clinical Data.

Although our prediction model could explain only a small amount of the variance in visual field progression, it may offer the possibility to identify subgroups of treated patients with high rates of visual field progression,…

Ocular hypertension and the risk of blindness.

The best estimates of the 15-year risk of unilateral blindness in patients with OHT, based on the currently available empirical data and an appropriate model, show that the risk is <10%.